



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/683,880	10/09/2003	Kun Ping Lu	BIZ-045CPCN	7888
959	7590	09/20/2006	EXAMINER	
LAHIVE & COCKFIELD 28 STATE STREET BOSTON, MA 02109			YAEN, CHRISTOPHER H	
			ART UNIT	PAPER NUMBER
			1643	

DATE MAILED: 09/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/683,880	LU ET AL.	
	Examiner Christopher H. Yaen	Art Unit 1643	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 05 July 2006.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 10,11,16,39,41 and 89-91 is/are pending in the application.
 4a) Of the above claim(s) 39 and 41 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 10,11,16 and 89-91 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>7/5/2006</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ . |

DETAILED ACTION

Re: Lu et al

Election/Restrictions

1. Applicant's election with traverse of group I (claims 1,2,10,11,16,28-30, and 46 specifically drawn to the detection of Pin1 protein) in the reply filed on 7/21/2006 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-9,12-15, 17-38,40, and 42-88 are canceled without prejudice or disclaimer. Claims 89-91 are newly added.
3. Claims 10-11,16,39,41,89-91 are pending, claims 39 and 41 are withdrawn from further consideration .
4. Claims 10,11,16, and 89-91 are examined on the merits.

Information Disclosure Statement

5. The Information Disclosure Statement filed on 7/5/2006 is acknowledged and considered. A signed copy of the IDS is attached hereto.

Claim Rejections - 35 USC § 112, 2nd paragraph

6. Claims 10,11,16,89-91 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 10,11,16, and 89-91 are rejected as vague and indefinite for reciting the term Pin1 as the sole means of identifying the claimed molecule. The use of laboratory designations only to identify a particular molecule renders the claims indefinite because different laboratories may use the same laboratory designations to define completely distinct molecules. The rejection can be obviated by amending the claims to specifically and uniquely identify NRG3, for example, by SEQ ID NO. and function of Pin1.

For the purpose of compact prosecution, the term Pin1 will be interpreted to be equivalent to peptidyl-prolyl isomerase.

Claim Rejections - 35 USC § 112, 1st paragraph

7. Claims 10, 11, 16, and 89-91 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. THIS IS A WRITTEN DESCRIPTION REJECTION.

The specification teaches that there are homologous genes which encode Pin1 related proteins or variants (see page 12-13). Therefore, the term Pin1 encompasses more than the full length protein of Pin1, but also Pin1 variants and homologs.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial

Art Unit: 1643

structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim is a recitation of the term "Pin1". Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Although drawn to DNA arts, the findings in *University of California v. Eli Lilly and Co.*, 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) and *Enzo Biochem, Inc. v. Gen-Probe Inc.* are relevant to the instant claims. The Federal Circuit addressed the application of the written description requirement to DNA-related inventions in *University Of California v. Eli Lilly and Co.*, 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997). The Court stated that" [a] written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as by structure, formula, [or] chemical name', of the claimed subject matter sufficient to distinguish it from other materials. " *Id.* at 1567, 43 USPQ2d at 1405. The court also stated that:

a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA" without more, is not an adequate written description of the genus because it does not distinguish the genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can

do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is.

Id. at 1568, 43 USPQ2d at 1406. The court concluded that "naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material." Id.

Finally, the court addressed the manner by which a genus of cDNAs might be described. "A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the genus." Id.

The Federal Circuit has recently clarified that a DNA molecule can be adequately described without disclosing its complete structure. See *Enzo Biochem, Inc. V. Gen-Probe Inc.*, 296 F.3d 1316, 63 USPQ2d 1609 (Fed. Cir. 2002). The *Enzo* court adopted the standard that "the written description requirement can be met by show[ing] that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics." *Id.* at 1324, 63 USPQ2d at 1613 (emphasis omitted, bracketed material in original).

The inventions at issue in *Lilly* and *Enzo* were DNA constructs *per se*, the holdings of those cases are also applicable to claims such as those at issue here. A disclosure that does not adequately describe a product itself logically cannot adequately describe a method of using that product.

Thus the instant specification may provide an adequate written description of Pin1, per *Lilly*, by structurally describing representative Pin1 proteins or by describing "structural features common to the members of the genus, which features constitute a substantial portion of the genus." Alternatively, per *Enzo*, the specification can show that the claimed invention is complete "by disclosure of sufficiently detailed, relevant identifying characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics."

In this case, the specification does not directly describe Pin1 useful in the claimed invention in a manner that satisfies either the *Lilly* or *Enzo* standards. Although the specification discloses Pin1, it is broadly described and this does not provide a description of the broadly claimed Pin1 that would satisfy the standard set out in *Enzo* because the specification provides no functional characteristics coupled to structural features.

Further, the specification also fails to describe Pin1 by the test set out in *Lilly* because the specification describes only Pin1 (i.e. full length). Therefore it necessarily fails to describe a representative number of such species. Thus the specification does not provide an adequate written description of Pin1 that is required to practice the

Art Unit: 1643

claimed invention. Since the specification fails to adequately describe the product to which the claimed method uses, it also fails to adequately describe the method.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

11. Claims 10,11,16, and 91 are rejected under 35 U.S.C. 103(a) as being unpatentable over any one of WO 97/17986, US Patent 5,972,697, or 5,952,467.

a. WO 97/17986 teaches a method of detecting malignant growth in tissue or bodily fluid comprising the contacting of the sample or fluid with a Pin1 antibody (see page 24, for example). These expression levels are also compared to normal controls. WO 97/17896 also indicate that high levels of Pin1 prevents the G2/M transition and that the depletion of Pin1 results in mitotic arrest, thereby indicating hyperproliferative disorders (see page 43). WO 97/17986 does not specifically teach that there be a specific comparison of the standard deviation between experimental tissue sample and normal controls.

b. US Patents 5,972,697 and 5,952,467 teach methods of detecting Pin1 in tissue samples or bodily fluids comprising the contacting of the sample or fluid with a Pin1 antibody. These expression levels are compared to normal controls. US Patents 5,972,697 and 5,952,467 also indicate that high levels of Pin1 prevent the G2/M transition and that the depletion of Pin1 results in mitotic arrest, thereby indicating hyperprolifertive disorders (see examples 7 and 9, for example). However, US Patents 5,972,697 and 5,952,467 do not specifically teach a specific comparison of the standard deviation between the experimental tissue sample and normal controls.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use Pin1 detection as a means to gauge hyperprolifertaive disorders and well as detecting malignant growth. One of skill in the

Art Unit: 1643

art would have been motivated in doing so because any one of WO 97/17986, US Patents 5,972,697 and 5952,467 taught that Pin1 can be detected in tissue sample or bodily fluids using a Pin1 specific antibody and comparing the expression levels assessed from the experimental sample to normal controls. Although none of the references relied upon specifically teach that a higher standard deviation is to be indicative of malignancy, it would have been within the realm of standard experimentation and optimization for one of skill in the art. It has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 220 F2d 454,456,105 USPQ 233; 235 (CCPA 1955). see MPEP § 2144.05 part II A.

Therefore, the claims are deemed obvious as a whole over the cited references.

Conclusion

No claim is allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The web article found at www.cancer.med.umich.edu/earn/typstage.htm was cited to show that general knowledge in the art with regard to the grading of cancers.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H. Yaen whose telephone number is 571-272-0838. The examiner can normally be reached on Monday-Friday 9-5.

Art Unit: 1643

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, Ph.D. can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christopher Yaen
Art Unit 1643
September 13, 2006

Christopher H. Yaen
CHRISTOPHER H. YAEN
PRIMARY EXAMINER